[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-control\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-control":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,57,83,102,138,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":4},"100623465","boosting-referrals-to-asthma-specialists-for-patients-seen-at-the-emergency-room-for-an-asthma-exacerbation-100623465",false,"NCT07396987","Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","Inclusion Criteria:\n\n* Age ≥18 years\n* Asthma diagnosis ≥1 year\n* Seen in ER for asthma exacerbation\n* Persistent asthma on controller therapy\n* ≥1 asthma exacerbation in prior year\n\nWe will allow for current smokers, vapers and cannabis users as long as they have not been diagnosed with COPD and have a smoking history \\\u003C10 pack-years.\n\nWe will allow for COPD as long as they are:\n\n1. never smokers\u002Fvapers\u002Fcannabis users; or\n2. former or current smokers\u002Fvapers\u002Fcannabis users with normal pulmonary function tests (PFT; FEV1\u002FFVC ratio of \\>70%) within 12 months of enrollment and a smoking history \\\u003C10 pack-years; or\n3. current or former smoker\u002Fvapers\u002Fcannabis users with obstruction on PFTs (FEV1\u002FFVC ratio of \\\u003C70%) but who demonstrate BOTH \\>10% acute bronchodilator reversibility AND a normal diffusing capacity both within 12 months of enrollment (stricter criteria than those used in the PREPARE trial (15) and a smoking history \\\u003C10 pack-years.\n\nExclusion Criteria:\n\n* Patients who have seen an asthma specialist (allergist or pulmonologist) for asthma in the past 2 years\n* Diagnosis of other pulmonary diseases (e.g., COPD, interstitial lung disease, etc.)","ALL","18 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study is testing a new way to help adults with asthma get follow up care after an emergency room (ER) visit for an asthma attack. Many people who come to the ER for asthma never see an asthma specialist afterward, even though specialists can offer treatments such as advanced inhalers or biologic medicines that may prevent future attacks.\n\nThe study will compare two approaches. One group will receive a telehealth appointment with an asthma specialist that is scheduled for them before they leave the ER. The other group will receive the usual care, which typically includes a standard referral but no scheduled appointment. All participants will be offered a prescription for standard controller medication at discharge.\n\nThe main question the study aims to answer is whether arranging a telehealth visit directly from the ER increases the number of patients who complete a follow up appointment with an asthma specialist within three months. The study will also look at whether this approach improves asthma control, reduces repeat ER visits, and helps patients better understand and use their asthma medications.\n\nThis research may help identify a practical way to improve access to asthma specialists and reduce the burden of asthma for patients who frequently rely on emergency care.",[25,26,27,28],"Asthma Attack","Asthma Control","Asthma Exacerbations","Asthma",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"asthma","asthma exacerbation","asthma control","inhaled corticosteroid","Long-Acting Beta-Agonist","Long-Acting Muscarinic Antagonist","Emergency Room","Asthma Control Test","Medication Adherence Report Scale for Asthma","Asthma Symptom Utility Index","barriers to care","social determinants of health","access to care","telehealth","telemedicine","NOT_YET_RECRUITING","2026-05-22",{"date":48,"type":49},"2026-05-26","ACTUAL",{"date":51,"type":19},"2026-06",{"date":53,"type":19},"2027-06",{"name":55,"class":56},"Juan Carlos Cardet","OTHER",{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":20,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100638378","the-development-of-the-walsh-asthma-self-management-programme-and-feasibility-of-implementation-in-adults-with-asthma-in-primary-care-100638378","NCT07609134","The Development of the Walsh Asthma Self-management Programme and Feasibility of Implementation in Adults With Asthma in Primary Care","Inclusion Criteria:\n\n* Adults over 18 years old\n* Adults who meet one of the following criteria:\n\na physician's diagnosis of asthma; coded as asthma (R96) as per the international classification of primary care (ICPC) or international classification of diseases (ICD) code J45 with associated use of asthma medications for 6 months prior to study enrolment.\n\nExclusion Criteria:\n\n* Adults under 18 years old\n* Adults with no diagnosis of asthma\n* Adults receiving asthma education in a specialist hospital or community setting\n* Adults unable to give informed consent\n* Smoking ≥ 10 Pack Year History",{"count":18,"type":19},[22],"Asthma is a common medical condition in Ireland. Adult patients tend to have periods when their asthma is stable and periods when it worsens. In order to reduce these periods of worsening asthma, effective ongoing management is required day to day by adults with asthma. Teaching adults how to manage their asthma effectively, plays a huge role in improving their asthma and having a better overall quality of life. This education on managing asthma has many different parts to it. Most adults will discover they have asthma through their general practitioner (GP) and it will be continued to be checked and managed through their GP or general practice nurse (GPN) in their primary care clinic for the duration of their lives.\n\nThis research study is taking place to find out if a new education programme, will help adults manage their asthma better and improve the symptoms of asthma, reducing its overall impact on day-to-day life. This study is also looking at how easy it is to introduce and for nurses to deliver this study within a GP\u002F primary care centre. This study is to find out if this education programme works in a real life setting and if it can lead to better control of asthma for adults.",[28,67,26],"Self-management",[28,69,32,70,71],"self-management education","primary care","nursing","RECRUITING","2026-05-19",{"date":75,"type":49},"2026-05-27",{"date":77,"type":19},"2026-05",{"date":79,"type":19},"2027-01",{"name":81,"class":56},"Royal College of Surgeons, Ireland",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":20,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100637843","replacing-gas-stoves-with-portable-electric-appliances-to-improve-indoor-air-quality-and-asthma-control-100637843","NCT07603206","Replacing Gas Stoves With Portable Electric Appliances to Improve Indoor Air Quality and Asthma Control","Inclusion Criteria:\n\n* Currently use gas stove for cooking or baking at least three times a week\n* Poorly controlled asthma as defined by an Asthma Control Questionnaire score of 1.5 or larger\n\nExclusion Criteria:\n\n* Impaired decision making capacity\n* Pregnancy",{"count":90,"type":19},20,[22],"The goals of this study are to determine if replacing gas stoves with portable electric hot plates and electric toaster ovens will improve indoor air quality and asthma control. Researchers will enroll participants with poorly controlled asthma and provide them with hot plates and toaster ovens to use instead of gas stoves. Researchers will measure indoor air quality about 1-2 weeks before and about 2-3 months after providing portable appliances. Participants will answer questions about their asthma symptoms and take lung function tests about 1-2 weeks before and about 2-3 months after using portable appliances.",[26],[30,95],"indoor air quality",{"date":46,"type":49},{"date":51,"type":19},{"date":99,"type":19},"2029-05",{"name":101,"class":56},"MetroHealth Medical Center",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":20,"phases":113,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100616746","phase-3-a-study-assessing-the-effect-of-dupilumab-on-inducing-clinical-remission-in-asthma-100616746","NCT07309614","A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma","A Multinational, Investigator-initiated, Parallel Group, Randomised, Double-blind, Placebo-controlled Phase 3b Superiority Trial Assessing the Effect of Dupilumab on Inducing Clinical Remission Outcomes in At-risk Type-2 Inflammatory Asthma (HOTHOT)","HOTHOT","INCLUSION CRITERIA\n\nStudy participants are eligible to be included in the study only if all of the following criteria apply:\n\nAge\n\n1. Participant must be 18-\\\u003C80 years of age at the time of signing the informed consent.\n\n   Type of participant and disease characteristics\n2. Physician diagnosis of asthma (according to GINA 2025) for ≥6 months, with documented historical airflow variability by one of the following:\n\n   * Positive reversibility test: ≥12% and 200 ml in FEV1 after SABA administration at any point prior to randomisation\n   * Airflow variability in clinic FEV1 \\>12% and 200 mL between historical clinical visits\n   * Positive bronchial challenge test: fall in FEV1 of ≥20% with standard doses of methacholine (\\\u003C16 mg\u002FmL or \\\u003C400mcg); or ≥10% with standardised hyperventilation, or exercise challenge test; or ≥15% with hypertonic saline or mannitol challenge\n   * Peak flow variability of \\>20% between two assessments\n3. Evidence of elevated type-2 biomarkers defined as both of:\n\n   1. peripheral BEC ≥ 0.3×109\u002FL at screening visit\n   2. FeNO ≥ 35 ppb at screening visit\n4. At least 1 asthma attack in the last 2 years, defined as acute asthma requiring SCS for ≥ 3 days or an emergency\u002Fhospital visit requiring SCS.\n5. Treatment and evident adherence to a stable at-least medium-dose ICS (fluticasone propionate equivalent \\>250 mcg\u002Fday) for at least 3 months (including run-in period) \\[additional controllers e.g. LABA, LAMA or LTA are allowed\\]. The ICS dosage will be defined as the dosage received on a regularly basis, excluding extra reliever doses taken in the context of anti-inflammatory reliever (AIR) therapy from the calculation. AIR is allowed in the context of the study. Thus, the high-dose ICS trial population (fluticasone propionate equivalent \\>500 mcg\u002Fday)\\* will represent patients who are not meeting the exacerbation criteria for biological reimbursement.\n\n   \\*As per section 6.2, we will cap recruitment to 60% of target population on medium-dose ICS, 40% on high-dose ICS, with randomisation also stratified by these categories.\n6. Presence of one (or more) of the following additional risk factors for asthma attacks32 at screening or baseline: (i) uncontrolled asthma symptoms indicated by ACQ5 score of ≥ 1.5; (ii) impaired lung function indicated by post-bronchodilator FEV1 of ≤ 80% predicted; (iii) high-dose maintenance ICS therapy (iv) severe asthma attack in past 1-\\\u003C12 months.\n\n   Sex, contraceptive\u002Fbarrier method and pregnancy testing requirements\n7. Female participants\n\n   a. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n   i. Is a woman of nonchildbearing potential (WONCBP) as defined in the Study Manual.\n\n   OR ii. Is a WOCBP and agrees to use a contraceptive method that is highly effective, with a failure rate of \\\u003C1%, during the intervention period (to be effective before starting the intervention) and for at least 12 weeks after the last dose of study intervention.\n\n   b. A WOCBP must have a negative highly sensitive serum pregnancy test at V1 (screening visit) and urine or serum pregnancy test (as required by local regulations) on Day 1 before the first dose of study intervention, c. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n\n   d. Additional requirements for pregnancy testing during and after study intervention are imposed.\n\n   e. The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a female participant with an early undetected pregnancy.\n\n   Informed consent\n8. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\n4.2 EXCLUSION CRITERIA\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical conditions\n\n1. Use of SCS \\\u003C 1 months prior to screening or on maintenance SCS.\n2. Current tobacco smoker or recently stopped smoker (\\\u003C6 months)\n3. Ex-smoker with greater than 10 pack-years AND post bronchodilator FEV1\u002FFVC ratio below the lower limit of normal according to GLI race-neutral standards. 69\n4. Documented nonadherence to ICS, defined as dispensing of less than 75% of the prescribed ICS dose over the past 12 months (or annualised if less than 12 months), based on pharmacy refill records checked at screening.\n5. Presence of significant and uncorrectable inhaler technique deficiencies, as assessed by the research team during inhaler technique evaluation at screening.\n6. Contra-indication to study drug\n7. Immunological disease, condition or medication that may affect the inflammatory response according to Investigator.\n8. History of other significant lung disease e.g. lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, clinically significant bronchiectasis, chronic obstructive lung disease, or Churg-Strauss.\n9. Severe concomitant illness (including known or suspected immunodeficiency) that, in the Investigator's judgement will adversely affect the participant's participation in the study.\n10. Active malignancy or history of malignancy within 5 years (except for basal cell carcinoma of the skin).\n11. Exposure to monoclonal antibody therapy for asthma or another investigational medicinal product within 5 half-lives of the drug.\n12. Eligibility to Dupilumab based on licensed and reimbursed indications in the participant's jurisdiction (e.g. nasal polyposis, atopic dermatitis, eosinophilic esophagitis, prurigo nodularis, etc.)\n13. Treatment with live (attenuated) vaccine in the past 4 weeks.\n14. Prohibited medication","79 Years",{"count":112,"type":19},150,[114],"PHASE3","This study tests whether an asthma medication called dupilumab can help people achieve complete asthma control (called \"remission\") when given earlier in their disease, before asthma becomes severe. Currently, most people with asthma only receive advanced treatments like biologics after their condition has worsened significantly and caused lung damage. This study explores whether treating high-risk patients earlier could prevent asthma attacks and lung function decline, potentially achieving remission before permanent damage occurs. The study is looking for adults aged 18-79 with moderate asthma who have had at least one asthma attack requiring steroid pills in the past 2 years, use medium or high-dose inhaled steroids regularly, have high levels of inflammation markers in their blood and breath tests, but don't yet meet criteria for severe asthma requiring biologic therapy. Participants receive either dupilumab or placebo injections every 2 weeks for one year, alongside their regular asthma medications. They attend clinic visits every 3 months for breathing tests, questionnaires, and safety monitoring. Neither participants nor doctors know who receives the real medication until the study ends. The goal is to learn whether early treatment with dupilumab helps more people achieve complete asthma control compared to standard care alone, potentially changing how asthma is treated from \"waiting until severe\" to \"preventing severe disease.\" The study runs in Canada, the United Kingdom, and Australia, involving 150 participants",[26],[28,118,119,120,121,122,123,124,125,126,127],"Asthma control","moderate asthma","dupilumab","remission","type-2 inflammation","blood eosinophils","feno","exacerbations","trial","RCT","2026-03-03",{"date":130,"type":49},"2026-03-04",{"date":132,"type":49},"2026-01-29",{"date":134,"type":19},"2030-01",{"name":136,"class":56},"Université de Sherbrooke",5,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":15,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":20,"phases":149,"briefSummary":150,"conditions":151,"keywords":155,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":164,"locationsCount":82},"100613041","pollution-intervention-to-impact-kids-asthma-study-100613041","NCT07261423","Pollution Intervention to Impact Kids Asthma Study","PIKAS","Inclusion Criteria:\n\n* A healthcare provider diagnosis of persistent asthma (Steps 2-5 as defined by US guidelines) or intermittent asthma (Step 1) + at least one severe asthma exacerbation (defined by American Thoracic Society (ATS)\u002FEuropean Respiratory Society (ERS) criteria as requiring at least 3 days of systemic steroids or an Emergency Department\u002FUrgent Care visit requiring systemic steroids) in the prior 12 months\n* Home access to a smartphone or internet\n* Primary residence in Allegheny County, PA\n* One participant per household\n* Age 8 -17 years\n* Healthcare provider evaluation for asthma in the prior year\n\nExclusion Criteria:\n\n* Diagnosis of other active chronic respiratory diseases (e.g., cystic fibrosis, bronchopulmonary dysplasia, etc.)\n* Neuromuscular disorder\n* Chronic disorder limiting independent ambulation (e.g., spastic quadriplegia, etc.)\n* Cyanotic heart disease\n* Plans to relocate from Allegheny County, PA in the next year (12 months)\n* Use of intranasal or oral\u002Fintramuscular\u002Fintravenous corticosteroids 4 weeks prior to randomization\n* Current participation in another asthma intervention trial","8 Years","17 Years",{"count":148,"type":19},351,[22],"The goal of this clinical trial is to learn if adding Air Quality Index (AQI) information to asthma action plans works to improve asthma outcomes in children. It will also learn about children with asthma who report being more sensitive to outdoor air pollution. The main questions it aims to answer are:\n\n* Does adding either information about the EPA-AQI or commercial AQI improve asthma outcomes over time?\n* Are there changes in nasal gene expression in children with asthma who report they are more sensitive to outdoor air pollution?\n\nResearchers will compare EPA-AQI and the commercial-AQI groups to a control group to either AQI works to improve asthma.\n\nParticipants will:\n\n* Receive standardized outdoor air pollution education and an asthma action plan\n* Provide nose and blood specimens\n* Have visits every 4 weeks for 48 weeks, 10 will be conducted by telephone calls and 3 visits will be in person.",[152,26,153,154],"Childhood Asthma","Asthma Exacerbation","Air Pollution, Risk Reduction Behaviors",[156,157,158],"childhood asthma","air quality index","AQI","2026-02-24",{"date":161,"type":49},"2026-02-27",{"date":159,"type":49},{"date":134,"type":19},{"name":165,"class":56},"University of Pittsburgh",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":15,"minAge":173,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":20,"phases":176,"briefSummary":177,"conditions":178,"keywords":183,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":199},"100608044","asthma-intervention-with-residential-ventilation-and-air-cleaner-airvac-study-100608044","NCT07196436","Asthma Intervention With Residential Ventilation and Air Cleaner (AIRVAC) Study","Energy Recovery Ventilation and Air Cleaner Interventions to Improve Indoor Air Quality, Mold Control, and Asthma-Related Health Outcomes Among Inner-City Children and Adults in Low-Income Households","Inclusion Criteria:\n\n* Individuals with physician-diagnosed asthma, including both adults and children aged 5-17\n* Homeowners living in the DFW metropolitan area, TX\n\nExclusion Criteria:\n\n* Participants living in homes with any smokers","5 Years",{"count":175,"type":19},80,[22],"The primary goal of this study is to investigate the comparative long-term (i.e., 1-year) effectiveness of energy recovery ventilators (ERVs) and portable air cleaners (PACs) in reducing indoor air pollutants and mold levels and improving asthma-related health outcomes in inner-city children and adults with asthma in low-income households in the Dallas-Fort Worth (DFW) metropolitan area, TX. Secondary goals include: (1) examining associations among asthma outcomes, exposure to indoor air pollutants and mold, and housing-related factors, (2) conducting a cost-benefit analysis of ERV and PAC interventions for improving IAQ, mold control, and health outcomes, and (3) evaluating the utility of cost-effective methods and protocols for measuring IAQ and mold for indoor air pollution epidemiology studies and for providing practical information to patients and their physicians. Using a double-blind, placebo-controlled randomized controlled trial, 80 households will be assigned to receive active or placebo versions of ERVs or PACs. Environmental exposures and housing conditions will be monitored alongside comprehensive health assessments, including lung function tests and validated surveys on asthma control, quality of life, stress, and sleep quality.",[26,179,180,181,182],"Pulmonary Function","Quality of Life","Stress","Sleep Quality",[28,26,179,184,180,181,182,185,186,187,188,189],"Lung Function","Indoor Air Quality","Residential Ventilation","Air Cleaner","Air Filtration","Mold","2025-10-27",{"date":192,"type":49},"2025-10-29",{"date":194,"type":49},"2025-10-10",{"date":196,"type":19},"2028-02-28",{"name":198,"class":56},"The University of Texas at Arlington",2]